Registry of Lobbyists
Subject matters | Details | Categories |
---|---|---|
Health
|
Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
|
Policies or Program
|
Health
|
Health Canada Regulatory Review of Drugs and Devices, including potential regulatory reforms with respect to drugs for rare diseases
|
Policies or Program
|
Health
|
Health Canada's Special Access Program (SAP) and associated regulations and guidelines
|
Policies or Program,
Regulation
|
Health
|
Health system policies with respect to pharmaceuticals, including drugs for rare diseases
|
Policies or Program
|
Economic Development,
Industry,
Intellectual Property,
Research and Development,
Science and Technology
|
Innovation agenda led by Innovation, Science and Economic Development Canada, particularly with respect to the life sciences industry
|
Policies or Program
|
Health
|
Patented Medicine Prices Review Board (PMPRB) guidelines with respect to non-excessive pricing of patented medicines
|
Policies or Program
|
Health
|
Patented Medicine Prices Review Board (PMPRB) regulations with respect to non-excessive pricing of patented medicines
|
Regulation
|
Subject matters | Details | Categories |
---|---|---|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada Regulatory Review of Drugs and Devices, including potential regulatory reforms with respect to drugs for rare diseases
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health Canada's Special Access Program (SAP) and associated regulations and guidelines
|
Policies or Program,
Regulation
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Health system policies with respect to pharmaceuticals, including drugs for rare diseases
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Innovation agenda led by Innovation, Science and Economic Development Canada, particularly with respect to the life sciences industry
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicine Prices Review Board (PMPRB) guidelines with respect to non-excessive pricing of patented medicines
|
Policies or Program
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Patented Medicine Prices Review Board (PMPRB) regulations with respect to non-excessive pricing of patented medicines
|
Regulation
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: